ReviewJournal for immunotherapy of cancer2026

Enhancing immune response in advanced HCC with PVTT: rivaroxaban as a core adjuvant in combined therapy.

Ying Yan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.